Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2019) 134 (Supplement_1): 4315.

https://doi.org/10.1182/blood-2019-126570

Published: 2019

Journal Articles

A Retrospective Review of Mercaptopurine Metabolism Reveals High Rate of Patients with Suboptimal Metabolites Successfully Corrected with Allopurinol

Lauren Marie Vasta, MD, Richard C Zanetti, MD, Dina S. Parekh, MD, Anne B. Warwick, MD MPH, Kenneth Lieuw, MD PhD

Blood (2019) 134 (Supplement_1): 3878.

https://doi.org/10.1182/blood-2019-126184

Published: 2019

Journal Articles

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Andrew Sochacki, MD, Cosmin Adrian Bejan, PhD, Shilin Zhao, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2959.

https://doi.org/10.1182/blood-2019-121513

Published: 2019

Journal Articles

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors

Ghassan Al-Shbool, MD, Sameer Desale, MS, Judith Veis, MD, Vera Malkovska, MD, Sanjal Desai, MD

Blood (2019) 134 (Supplement_1): 2912.

https://doi.org/10.1182/blood-2019-129558

Published: 2019

Journal Articles

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Jayshree Thorat, MD, Swaratika Majumdar, MDDM, Hasmukh Jain, MD DM, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM

Blood (2019) 134 (Supplement_1): 2914.

https://doi.org/10.1182/blood-2019-128755

Published: 2019

Journal Articles

Complete Hematologic and Cytogenetic Remission of Acute Myeloid Leukemia in an Elderly Patient Treated with Decitabine and Venetoclax: A Case Report

Hanrry Jerry Paredes, MD MT(ASCP), M. Francisco Gonzalez, MD

Blood (2019) 134 (Supplement_1): 5189.

https://doi.org/10.1182/blood-2019-132019

Published: 2019

Journal Articles

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Kylee L Martens, MD, Parisa R Khalighi, BS, Shan Li, PharmD, Andrew A White, MD, Emily Silgard, MS, Deborah Frieze, PharmD, Elihu H. Estey, MD, David A. Garcia, MD, Sangeeta R Hingorani, MD MPH, Ang Li, MD

Blood (2019) 134 (Supplement_1): 4674.

https://doi.org/10.1182/blood-2019-124058

Published: 2019

Journal Articles

Role of Echocardiography and Cardiac Biomarkers in Early Detection of Hematopoietic Stem Cell Transplantation Associated Cardiotoxicity

Ana Carolina Oliver, MD, Roberto Superchi, MD, Superchi Federico, MD, Canabal Matilde, MD, Jubin Silvana, Lic, Carolina Errecarte, MD, Caneiro Ada, MD, Silvia Pierri, MD, Sebastian Galeano, MD, Eloisa Riva, MD, Bello Laura, MD, Regis Gai, MD, Miller Andrew, MD, Pablo J. Muxi, MD, Ricardo Fabian Mosquera, MD

Blood (2019) 134 (Supplement_1): 5688.

https://doi.org/10.1182/blood-2019-127680

Published: 2019

Journal Articles

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Zheng Wei, MD, Yian Zhang, Jing Li, MD, Peng Liu, MD

Blood (2019) 134 (Supplement_1): 1908.

https://doi.org/10.1182/blood-2019-127023

Published: 2019

Journal Articles

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

Janna Radtchenko, Daniel Lyons, Yvonne Barnes, Scott Milligan, Edward Drea, PharmD

Blood (2019) 134 (Supplement_1): 2203.

https://doi.org/10.1182/blood-2019-124319

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Jun Zhu, MD PhD, Junning Cao, MD, Lugui Qiu, MD PhD, Junyuan Qi, MD, Yuqin Song, MD PhD, Meifeng Tu, MD PhD, Dongmei Ji, MD PhD, Weina Shen, MD, Mingyuan Sun, MD, Ye Hua, MD, Chen Yang, MD, Chen Yu, MD, Jian Wang, PhD, Guangxiu Dai, PhD, Weiguo Su, PhD

Blood (2018) 132 (Supplement 1): 5324.

https://doi.org/10.1182/blood-2018-99-111648

Published: 2018

Journal Articles

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Junyuan Qi, PhD, Yuqin Song, MD PhD, Bo Jiang, PhD, Jianyong Li, PhD, Meifeng Tu, PhD, Lingyan Ping, MD PhD, Zengjun Li, PhD, Wei Xu, MD PhD, Huayuan Zhu, MD PhD, Jun Zhu, MD PhD, Hanying Bao, MD PhD, Zusheng Xu, PhD, Lugui Qiu, MD PhD

Blood (2018) 132 (Supplement 1): 5332.

https://doi.org/10.1182/blood-2018-99-110585

Published: 2018

Journal Articles

Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data

Regina M Myers, MD, Kelly D Getz, PhD, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Rebecca Citrin, MD, Caitlin W Elgarten, MD, Benjamin L Laskin, MD, Joseph P. Horowitz, Brian T. Fisher, DO, Richard Aplenc, MD PhD

Blood (2018) 132 (Supplement 1): 830.

https://doi.org/10.1182/blood-2018-99-114883

Published: 2018

Journal Articles

Pilot Study of Tocilizumab in Patients with HIV and Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease

Ramya Ramaswami, MBBS, MPH, Kathryn Lurain, MD MPH, Anaida Widell, Mark N. Polizzotto, Priscila H. Goncalves, MD, Matthew Lindsley, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2018) 132 (Supplement 1): 2894.

https://doi.org/10.1182/blood-2018-99-113119

Published: 2018

Journal Articles

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Stefan Klaus Barta, MD MRCP, MS, Noah Kornblum, MD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Elizabeth Handorf, Joseph Sparano, MD, Richard Piekarz, MD PhD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2018-99-116991

Published: 2018

Journal Articles

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia

Pankit Vachhani, MD, Craig Freyer, PharmD, BCOP, Jeffrey Baron, PharmD, BCOP, Austin Miller, PhD, Meir Wetzler, MD, James E. Thompson, MD, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2017) 130 (Supplement 1): 5052.

https://doi.org/10.1182/blood.V130.Suppl_1.5052.5052

Published: 2017

Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD

Blood (2017) 130 (Supplement 1): 3131.

https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131

Published: 2017

Journal Articles

Hyperuricemia and Musculoskeletal Complications in Thalassemia Patients

Juthatip Chaloemwong, MD, Adisak Tantiworawit, MD, Worawit Louthrenoo, MD, Thanawat Rattanathammethee, MD, Sasinee Hantrakool, MD, Chatree Chai-Adisaksopha, MD, Ekarat Rattarittamrong, MD, Lalita Norasetthada, MD

Blood (2017) 130 (Supplement 1): 4761.

https://doi.org/10.1182/blood.V130.Suppl_1.4761.4761

Published: 2017

Journal Articles

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

William G Wierda, MD PhD, Matthew S. Davids, MD, Richard R. Furman, Bruce D. Cheson, MD, Paul M. Barr, MD, Herbert Eradat, Leonard Heffner, MD, Jeffrey Jones, MD, Lang Zhou, Maria Verdugo, MD, Rod A. Humerickhouse, Jalaja Potluri, Michael Choi, MD

Blood (2017) 130 (Supplement 1): 3025.

https://doi.org/10.1182/blood.V130.Suppl_1.3025.3025

Published: 2017

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

NARROW

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

A Retrospective Review of Mercaptopurine Metabolism Reveals High Rate of Patients with Suboptimal Metabolites Successfully Corrected with Allopurinol

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Complete Hematologic and Cytogenetic Remission of Acute Myeloid Leukemia in an Elderly Patient Treated with Decitabine and Venetoclax: A Case Report

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Role of Echocardiography and Cardiac Biomarkers in Early Detection of Hematopoietic Stem Cell Transplantation Associated Cardiotoxicity

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data

Pilot Study of Tocilizumab in Patients with HIV and Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Hyperuricemia and Musculoskeletal Complications in Thalassemia Patients

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only